IGF2BP2

Across TCGA pan-cancer cohorts, IGF2BP2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated IGF2BP2 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGF2BP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGF2BP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, KIRC, and BLCA are the cancer types where IGF2BP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.325	0.688	<.001	36	view →
KIRC	OS	Median	All	0.138	0.655	.021	12	view →
BLCA	OS	Median	III,IV	0.126	0.588	<.001	12	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
PAAD	OS	Median	All	0.117	0.640	.007	9	view →
UCEC	DFS	Median	All	0.924	0.616	.020	4	view →
BRCA	DFS	Median	All	0.647	0.903	.005	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

IGF2BP2–LUAD (DFS)

Open the LUAD breakdown →